A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch

por Vagenas, Vassileios, Vlachos, Georgios S, Vlachou, Nikoleta, Liakopoulos, Dimitrios, Kalaitzakis, Michail E, Vikelis, Michail
Publicado 2015

Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease

por Pey, Peixuan, Pearce, Ronald KB, Kalaitzakis, Michail E, Griffin, W Sue T, Gentleman, Steve M
Publicado 2014

Neuronal pentraxin II is highly upregulated in Parkinson’s disease and a novel component of Lewy bodies

por Moran, Linda B., Hickey, Lorraine, Michael, Gregory J., Derkacs, Maria, Christian, Lynne M., Kalaitzakis, Michail E., Pearce, Ronald K. B., Graeber, Manuel B.
Publicado 2007

Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson’s disease with cognitive decline

por Liu, Alan King Lun, Chau, Tsz Wing, Lim, Ernest Junwei, Ahmed, Idil, Chang, Raymond Chuen-Chung, Kalaitzakis, Michail E., Graeber, Manuel B., Gentleman, Steve M., Pearce, Ronald K. B.
Publicado 2019